Agreements reached under this partnership
Business alliance- 1
The companies plan to jointly explore the structural analysis of novel macrocycles, peptides, peptoids and other compounds beyond the Rule of 5 that interact with promising mRNA motifs.
- 2
They aim to generate commercially attractive drug candidates, deepen their understanding of structure-activity relationships in RNA recognition, and establish design criteria to support future drug discovery.
- 3
In the initial research stage, the companies will evaluate the binding of SpiroChem's compounds to several mRNA targets discovered by VIS.
- 4
In parallel with the research activities, the companies plan to continue discussing the details of the joint research to be conducted in the next research stage.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
No upfront fees or other payments are expected to be made or received in connection with the signing of this agreement. The research costs associated with this joint discovery research have already been included in VIS's annual budget for the fiscal year ending December 2026, and no material impact on future results is expected.
| Item | Details |
|---|---|
| Name of alliance partner | SpiroChem AG |
| Alliance partner's business activities | Deep expertise in compounds such as macrocycles, peptides and peptoids, outstanding capabilities in complex medicinal chemistry, small-molecule compound libraries, and medicinal chemistry |
| Alliance partner's location | Basel, Switzerland |
| Type of alliance | Business alliance |
| Details of the alliance | The companies plan to jointly explore the structural analysis of novel macrocycles, peptides, peptoids and other compounds beyond the Rule of 5 that interact with promising mRNA motifs., They aim to generate commercially attractive drug candidates, deepen their understanding of structure-activity relationships in RNA recognition, and establish design criteria to support future drug discovery., In the initial research stage, the companies will evaluate the binding of SpiroChem's compounds to several mRNA targets discovered by VIS., In parallel with the research activities, the companies plan to continue discussing the details of the joint research to be conducted in the next research stage. |
| Contract Date | 11 May 2026 |
| Impact on Business Performance | No upfront fees or other payments are expected to be made or received in connection with the signing of this agreement. The research costs associated with this joint discovery research have already been included in VIS's annual budget for the fiscal year ending December 2026, and no material impact on future results is expected. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The agreement aims to create small-molecule compounds targeting mRNA by combining SpiroChem's expertise in compounds such as macrocycles, peptides and peptoids with VIS's AI-driven mRNA-targeted drug discovery platform, aibVIS, and cell-based experimental technologies.